Theralase Technologies Inc. (CVE:TLT)

PRESS RELEASE

published on 10/05/2023 at 13:00, 3 years ago

Theralase(R) Files US Patent for Enhanced Immunotherapy
PRESS RELEASE

published on 09/29/2023 at 13:00, 3 years 1 month ago

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
PRESS RELEASE

published on 09/27/2023 at 13:00, 3 years 1 month ago

Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
PRESS RELEASE

published on 09/21/2023 at 22:35, 3 years 1 month ago

Theralase(R) Grants Stock Options
PRESS RELEASE

published on 09/07/2023 at 10:30, 3 years 1 month ago

Theralase(R) Closes Private Placement Equity Financing
PRESS RELEASE

published on 08/29/2023 at 22:30, 3 years 2 months ago

Theralase Release’s 2Q2023 Interim Financial Statements
PRESS RELEASE

published on 06/30/2023 at 22:35, 3 years 4 months ago

Theralase(R) Closes Non-Brokered Private Placement Equity Financing
PRESS RELEASE

published on 06/06/2023 at 13:00, 3 years 4 months ago

Theralase(R) Announces Appointment of New Independent Director
PRESS RELEASE

published on 05/31/2023 at 03:30, 3 years 5 months ago

Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
PRESS RELEASE

published on 05/31/2023 at 01:35, 3 years 5 months ago

Theralase(R) Releases 1Q2023 Interim Financial Statements

Published on 10/30/2026 at 23:00, 1 day 23 hours ago

BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 20:42, 2 days 2 hours ago

TINC and PMV invest in Storm Group (B)
Published on 10/30/2026 at 18:00, 2 days 4 hours ago

2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 10 hours ago

Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:45, 2 days 14 hours ago

Share buyback

News